Oxford BioTherapeutics ("OBT"), is a clinical stage oncology company focused on the discovery and development of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies enabled by its OGAP®-Verify platform today announced a multi-year, selective target collaboration with Bristol Myers Squibb (NYSE:BMY, "BMS"))) focussed on the discovery and development of novel T-cell engager therapies for solid tumours.

OBT will leverage its proprietary OGAP®-Verify target discovery and validation platform, to identify novel, tumour-selective targets for solid cancers and generate next-generation T-cell engager molecules. The collaboration extends beyond discovery, with OBT assuming responsibility for the design and delivery of development candidates, highlighting the company's expanding evolution into a fully integrated discovery and preclinical development platform. Subsequent research, development and commercialisation activities for these targets will be led by BMS.

Under the terms of the agreement, OBT will receive an upfront inclusive of research funding and the potential for significant downstream milestone payments and royalties on commercialised products from BMS. Financial terms were not disclosed.

The collaboration with BMS marks OBT's third partnership with a major pharmaceutical company in the past 12 months, following strategic partnerships with GSK and Roche in 2025.